Your dosage of VICTRELIS will be based on several factors, such as whether you have liver cirrhosis. In general, the recommended dose is 800 mg (four capsules), three times a day. Take each dose seven to nine hours apart. It is important to remember to take this medicine as directed -- missing doses increases the risk of the virus developing resistance.
There is only one standard recommended dose of VICTRELIS™ (boceprevir). However, the length of treatment will depend on a variety of factors, including:
- Whether you have liver cirrhosis
- Whether you have been treated previously for hepatitis C
- How you respond to treatment.
As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.
The recommended VICTRELIS dosage for treating genotype 1 chronic hepatitis C is 800 mg, three times a day. Doses should be given about seven to nine hours apart with a meal or snack.
VICTRELIS must be used in combination with peginterferon alfa and ribavirin. You will take peginterferon and ribavirin for four weeks, and then start VICTRELIS at week 5. Your healthcare provider will check your viral levels at weeks 8, 12, and 24 to determine your optimal duration of treatment.
People without cirrhosis who have undetectable viral levels at weeks 8 and 24 will continue VICTRELIS, peginterferon alfa, and ribavirin until they have received 28 total weeks of treatment -- if they have never been treated in the past for hepatitis C.
However, those who have been treated in the past and who have undetectable viral levels at weeks 8 and 24 will continue VICTRELIS, peginterferon alfa, and ribavirin for a total of 36 weeks of treatment.
People without cirrhosis of the liver who have detectable viral levels at week 8 but undetectable levels at week 24 will receive VICTRELIS, peginterferon alfa, and ribavirin for a total of 36 weeks, and then peginterferon alfa and ribavirin for an additional 12 weeks, for a total 48 weeks of treatment.
Some people may receive 4 weeks of peginterferon alfa and ribavirin followed by 44 weeks of VICTRELIS, peginterferon alfa, and ribavirin. These people include those who:
- Were previously treated with peginterferon alfa and ribavirin, but did not have an adequate viral decrease after 12 weeks
- Respond poorly to the initial four-week treatment with peginterferon alfa and ribavirin
- Have liver cirrhosis at the start of treatment.
If an inadequate response to treatment is observed at week 12, treatment may be stopped then. Treatment also will be stopped if the virus is still detectable after 24 weeks of treatment.